来那度胺单药治疗JAK2（V617F）阳性、del（5）（q13q33）骨髓增生异常综合征所致急性髓系白血病的血液学和细胞遗传学反应 - Suppr

Suppr

超能文献

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

作者信息

Mesa R A, Tefferi A, Li C-Yang, Steensma D P

出版信息

Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.

DOI:10.1038/sj.leu.2404398

PMID:16990762

Abstract

摘要

相似文献

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.来那度胺单药治疗JAK2（V617F）阳性、del（5）（q13q33）骨髓增生异常综合征所致急性髓系白血病的血液学和细胞遗传学反应

Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.来那度胺对一名伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效。

Leuk Lymphoma. 2010 Oct;51(10):1941-3. doi: 10.3109/10428194.2010.506567.

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.来那度胺治疗后细胞遗传学完全缓解的伴有del(5q)的骨髓增生异常综合征患者发生急性白血病急变。

Leuk Res. 2011 Jun;35(6):e69-70. doi: 10.1016/j.leukres.2010.12.019. Epub 2011 Jan 12.

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.来那度胺治疗伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.接受来那度胺治疗后未能获得持续红细胞或细胞遗传学缓解的 del(5q) MDS 患者，其克隆进化和 AML 进展的风险增加。

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.伴有del(5q)和JAK2 V617F突变的骨髓增生异常综合征在长期使用来那度胺治疗后转化为急性髓系白血病，并伴有额外的染色体异常。

Leuk Lymphoma. 2017 Oct;58(10):2511-2513. doi: 10.1080/10428194.2017.1295146. Epub 2017 Feb 28.

Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.伴有5号染色体长臂缺失（del(5q)）和JAK2（V617F）突变的骨髓增生异常综合征转化为具有复杂核型的急性髓系白血病。

Ann Hematol. 2016 Feb;95(3):525-7. doi: 10.1007/s00277-015-2584-8. Epub 2016 Jan 11.

Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).来那度胺治疗伴有del(5q)和del(9q)的骨髓增生异常综合征患者的疗效及细胞遗传学完全缓解情况

Leuk Res. 2010 Jul;34(7):e169-72. doi: 10.1016/j.leukres.2009.12.015. Epub 2010 Jan 31.

Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.来那度胺治疗仅7天后，一名患有骨髓增生异常综合征且5号染色体长臂缺失患者的血液学和细胞遗传学反应。

Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).一例伴有5号染色体长臂缺失（del(5q)）和20号染色体长臂缺失（del(20q)）的骨髓增生异常综合征患者对极短疗程来那度胺治疗的延迟但持久的反应及意外的克隆重新分布

Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.

引用本文的文献

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).来那度胺对伴有5号染色体长臂缺失的骨髓增生异常综合征患者的疗效：来自希腊国家骨髓增生异常综合征与再生障碍性贫血综合征登记处（EAKMYS）的真实世界数据。

Cancers (Basel). 2025 Apr 22;17(9):1388. doi: 10.3390/cancers17091388.

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.如何管理异体干细胞移植候选患者的骨髓纤维化。

Cells. 2022 Feb 5;11(3):553. doi: 10.3390/cells11030553.

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.在复发、难治或不适合其他治疗方案的老年新诊断急性髓系白血病患者中持续高剂量使用来那度胺——一项I期研究的结果

Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31.

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.伴有孤立 del(5q)和 JAK2(V617F)突变的骨髓增生异常综合征：简要综述，重点是来那度胺治疗。

Onco Targets Ther. 2014 Jun 13;7:1043-50. doi: 10.2147/OTT.S59628. eCollection 2014.

Thalidomide treatment in a myelofibrosis patient with leukemia transformation.沙利度胺治疗一名发生白血病转化的骨髓纤维化患者。

Int J Hematol. 2014 Feb;99(2):188-92. doi: 10.1007/s12185-013-1478-6. Epub 2013 Dec 4.

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.一项单独使用来那度胺治疗染色体 5 异常的复发/难治性急性髓系白血病或高危骨髓增生异常综合征的 II 期研究。

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):341-4. doi: 10.1016/j.clml.2012.04.001. Epub 2012 May 10.

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.一项来那度胺单药治疗伴 5q 缺失的急性髓系白血病患者的 2 期研究：西南肿瘤协作组研究 S0605。

Blood. 2011 Jul 21;118(3):523-8. doi: 10.1182/blood-2011-02-337303. Epub 2011 May 6.

Initial testing of lenalidomide by the pediatric preclinical testing program.儿科临床前试验计划对来那度胺的初步测试。

Pediatr Blood Cancer. 2011 Oct;57(4):606-11. doi: 10.1002/pbc.22877. Epub 2011 Feb 25.

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.免疫调节药物来那度胺（Revlimid，通用名：lenalidomide）和CC - 4047通过激活自然杀伤细胞（NK细胞）诱导血液肿瘤细胞和实体瘤细胞凋亡。

Cancer Immunol Immunother. 2008 Dec;57(12):1849-59. doi: 10.1007/s00262-008-0512-7. Epub 2008 Apr 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验